Manchester Capital Management’s Charles River Laboratories CRL Stock Holding History

Manchester Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36K	Hold	6	–	–	﹤0.01%	1116
2026 Q1	$1.03K	Hold	6	–	–	﹤0.01%	1125
2025 Q4	$1.2K	Sell	6 -10	-63%	-$1.81K	﹤0.01%	1106
2025 Q3	$2.5K	Hold	16	–	–	﹤0.01%	1049
2025 Q2	$2.43K	Buy	16 +15	+1,500%	+$2K	﹤0.01%	983
2025 Q1	$151	Sell	1 -95	-99%	-$15.9K	﹤0.01%	1148
2024 Q4	$17.7K	Buy	96 +22	+30%	+$4.24K	﹤0.01%	722
2024 Q3	$14.6K	Buy	74 +50	+208%	+$10.4K	﹤0.01%	736
2024 Q2	$4.96K	Buy	+24	New	+$5.44K	﹤0.01%	847
2021 Q3	–	Sell	-45	Closed	-$17K	–	1047
2021 Q2	$17K	Buy	+45	New	+$15K	﹤0.01%	452
2021 Q1	–	Sell	-3	Closed	-$1K	–	673
2020 Q4	$1K	Buy	+3	New	+$714	﹤0.01%	643

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Manchester Capital Management's CRL Position: Q2 2026 in Review

Manchester Capital Management held its Charles River Laboratories (CRL) position steady in Q2 2026 at 6 shares worth $1.36K. The position accounts for ﹤0.01% of the portfolio, ranked #1116.

Manchester Capital Management first reported a position in CRL in Q4 2020 and has held it in 11 quarters since. The position peaked at $17.7K in Q4 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Manchester Capital Management held 6 shares of Charles River Laboratories worth $1.36K as of Q2 2026.
Manchester Capital Management left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #1116 holding.
Manchester Capital Management first reported a position in Charles River Laboratories in Q4 2020 and has held it in 11 quarters since.
Manchester Capital Management's Charles River Laboratories position peaked at $17.7K in Q4 2024.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.